Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort

Gareth Rivalland*, Paul Mitchell, Carmel Murone, Khashayer Asadi, Adrienne L. Morey, Maud Starmans, Paul C. Boutros, Marzena Walkiewicz, Benjamin Solomon, Gavin Wright, Simon Knight, Thomas John

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalTranslational Lung Cancer Research
Volume8
Issue number2
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Immunohistochemistry
  • in situ hybridisation
  • mesenchyme to epithelial transition receptor (MET receptor)
  • mesenchyme to epithelial transition amplification (MET amplification)
  • non-small cell lung cancer (NSCLC)
  • PHASE-II TRIAL
  • PROGNOSTIC VALUE
  • MET
  • ERLOTINIB
  • ONARTUZUMAB
  • ACTIVATION
  • MUTATIONS
  • TARGET

Cite this

Rivalland, G., Mitchell, P., Murone, C., Asadi, K., Morey, A. L., Starmans, M., Boutros, P. C., Walkiewicz, M., Solomon, B., Wright, G., Knight, S., & John, T. (2019). Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. Translational Lung Cancer Research, 8(2), 167-175. https://doi.org/10.21037/tlcr.2019.03.11